Theriva Biologics shares are trading higher after the company announced FDA orphan drug designation to VCN-01 for pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has announced that the FDA has granted orphan drug designation to VCN-01 for pancreatic cancer, leading to a rise in the company's share prices.
June 28, 2023 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics' shares are trading higher following the FDA's orphan drug designation to VCN-01 for pancreatic cancer.
The FDA's orphan drug designation for VCN-01, a drug developed by Theriva Biologics for pancreatic cancer, is a significant regulatory milestone for the company. This designation can lead to various benefits for the company, including tax credits, market exclusivity, and waiver of certain fees, which can positively impact the company's financials and hence its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100